Home About Pipeline Team News Contact Us

Latest from PrevEp

Clinical milestones, peer-reviewed publications, grants, and company developments in epilepsy research and drug development.

News & Announcements

March 2026

Comprehensive Seletracetam Review Published in CNS Drugs

A detailed review of seletracetam's pharmacology, clinical profile, and the development of the novel intranasal formulation published in CNS Drugs. The paper covers preclinical and clinical data, including first-in-human intranasal administration results.

Read More
2026

First-in-Human Intranasal Seletracetam Published in Annals of Neurology

Original clinical data from the first-in-human use of intranasal seletracetam in a patient with reading epilepsy, published in Annals of Neurology — one of the most prestigious journals in neurology.

Read Paper
January 2026

Wolfgang Löscher Named Highly Ranked Scholar by ScholarGPS

PrevEp's Chief Scientific Officer received the inaugural "Highly Ranked Scholar" designation. ScholarGPS analyzed publication records, citations, and scholarly contributions across 30+ million scholars worldwide. Dr. Löscher ranked #1 in the field of epilepsy.

Read More
December 2025

First-in-Human Intranasal Seletracetam Administration

PrevEp team reported the first-in-human administration of intranasal seletracetam in a drug-resistant reflex epilepsy case at the American Epilepsy Society Annual Meeting.

View Abstract
December 2025

New Publications Across All Pipeline Programs

Multiple peer-reviewed publications released covering intranasal seletracetam first-in-human studies, IV topiramate preclinical data, and combination therapy studies in epilepsy models.

View Publications →
April 2025

Eugen Trinka Joins PrevEp as VP of Clinical Trials

Professor Eugen Trinka, Chairman of the Department of Neurology at Paracelsus Medical University and Vice President of the International League Against Epilepsy (ILAE), joins PrevEp as Vice President of Clinical Trials.

Meet the Team →
September 2023

NINDS SBIR Award for Intravenous Topiramate

PrevEp received National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research (SBIR) award 1R43NS132659: "Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate."

September 2021

NINDS SBIR Award for Network Pharmacology

PrevEp received NINDS SBIR award 1R43NS119081: "Network Pharmacology for epilepsy Prevention." This grant supports PrevEp's pioneering approach to epilepsy prevention through multi-target combination strategies.

Peer-reviewed research

Our team's work is published in top-tier neurology and pharmacology journals.

PrevEp006 Intranasal Seletracetam
2026 CNS Drugs

Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy

Löscher W, Rundfeldt C, Trinka E, Koepp MJ, Klein P

Download PDF
2026 Annals of Neurology

Intranasal Seletracetam in a Patient with Reading Epilepsy — First-in-Human Use

Koepp MJ, et al.

Download PDF
2025 Epilepsy & Behavior

Phase 2a Photoparoxysmal Response Study with Oral Seletracetam

Löscher W, Kasteleijn-Nolst Trenité D, et al.

Download PDF
2025

Phase 2a Photoparoxysmal Response: Seletracetam Combined with Levetiracetam

PrevEp Research Team

Download PDF
PrevEp004 Intravenous Topiramate
2025 Epilepsia

Topiramate for the Treatment of Neonatal Seizures and Beyond

Löscher W, et al.

Download PDF
2023 Epilepsy & Behavior

First-in-Human Meglumine-based IV Topiramate for Seizure Emergencies

Löscher W, Trinka E, Apostolakopoulou E, et al.

Download PDF
2023 Epilepsia

Meglumine-based IV Topiramate: Preclinical Pharmacokinetics and Tolerability

Rundfeldt C, et al.

Download PDF
PrevEp002 Combination Epilepsy Prevention
2024 Experimental Neurology

Ceftriaxone, Atorvastatin, Levetiracetam in Rat Post-Traumatic Epilepsy Model

Hameed MQ, et al.

Download PDF
2021 Neurobiology of Disease

PrevEp002 in Mouse Kainate Epileptogenesis Model

Löscher W, Welzel L, Klein P, et al.

Download PDF

Explore our science

Learn more about our innovative pipeline or get in touch to discuss partnership opportunities.